Tags

Type your tag names separated by a space and hit enter

Chemotherapy of leprosy.
J Indian Med Assoc. 2004 Dec; 102(12):695-6, 698.JI

Abstract

The WHO MDT regimens have proved highly successful in preventing relapse of leprosy cases. It has indirectly lad to marked reduction in prevalence of disabilities. For PB leprosy, rifampicin 600 mg monthly and 100 mg dapsone daily for a total of 6 months therapy is required. For MB leprosy clofazimine 300 mg once monthly, supervised and 50 mg daily self administered is added. For single skin lesion the current WHO recommendation is 600 mg rifampicin + 400 mg ofloxacin + 100 mg minocycline given as a single dose for adults. Dose adjustment for children and clinical information have been discussed in a nutshell. A number of trials are going on, some are yet to be completed which do offer the prospect of perhaps simplifying therapy and improving with shorter duration.

Authors+Show Affiliations

Department of Dermatology, STD and Leprosy, Calcutta School of Tropical Medicine, Kolkata 700 073.No affiliation info available

Pub Type(s)

Guideline
Journal Article
Practice Guideline

Language

eng

PubMed ID

15871354

Citation

Biswas, Surajit Kumar, and WHO. "Chemotherapy of Leprosy." Journal of the Indian Medical Association, vol. 102, no. 12, 2004, pp. 695-6, 698.
Biswas SK, WHO. Chemotherapy of leprosy. J Indian Med Assoc. 2004;102(12):695-6, 698.
Biswas, S. K. (2004). Chemotherapy of leprosy. Journal of the Indian Medical Association, 102(12), 695-6, 698.
Biswas SK, WHO. Chemotherapy of Leprosy. J Indian Med Assoc. 2004;102(12):695-6, 698. PubMed PMID: 15871354.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chemotherapy of leprosy. AU - Biswas,Surajit Kumar, AU - ,, PY - 2005/5/6/pubmed PY - 2005/6/30/medline PY - 2005/5/6/entrez SP - 695-6, 698 JF - Journal of the Indian Medical Association JO - J Indian Med Assoc VL - 102 IS - 12 N2 - The WHO MDT regimens have proved highly successful in preventing relapse of leprosy cases. It has indirectly lad to marked reduction in prevalence of disabilities. For PB leprosy, rifampicin 600 mg monthly and 100 mg dapsone daily for a total of 6 months therapy is required. For MB leprosy clofazimine 300 mg once monthly, supervised and 50 mg daily self administered is added. For single skin lesion the current WHO recommendation is 600 mg rifampicin + 400 mg ofloxacin + 100 mg minocycline given as a single dose for adults. Dose adjustment for children and clinical information have been discussed in a nutshell. A number of trials are going on, some are yet to be completed which do offer the prospect of perhaps simplifying therapy and improving with shorter duration. SN - 0019-5847 UR - https://www.unboundmedicine.com/medline/citation/15871354/Chemotherapy_of_leprosy_ L2 - https://medlineplus.gov/mycobacterialinfections.html DB - PRIME DP - Unbound Medicine ER -